Case Report: Kanamycin Ototoxicity and MDR-TB Treatment Regimen

Bahru Mantefardo,1 Gizaw Sisay2 1Department of Internal Medicine, School of Medicine, College of Medicine and Health Sciences, Dilla University, Dilla, Ethiopia; 2School of Public Health, College of Medicine and Health Sciences, Dilla University, Dilla, EthiopiaCorrespondence: Gizaw Sisay Tel +25191...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Mantefardo B, Sisay G
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2021
Materias:	multiple-drug resistant tuberculosis aminoglycosides ototoxicity ethiopia Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/ace0f7f7de024dfda1bd22822cbdae6a
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:ace0f7f7de024dfda1bd22822cbdae6a
record_format	dspace
spelling	oai:doaj.org-article:ace0f7f7de024dfda1bd22822cbdae6a2021-11-25T18:55:29ZCase Report: Kanamycin Ototoxicity and MDR-TB Treatment Regimen1179-142Xhttps://doaj.org/article/ace0f7f7de024dfda1bd22822cbdae6a2021-11-01T00:00:00Zhttps://www.dovepress.com/case-report-kanamycin-ototoxicity-and-mdr-tb-treatment-regimen-peer-reviewed-fulltext-article-IMCRJhttps://doaj.org/toc/1179-142XBahru Mantefardo,1 Gizaw Sisay2 1Department of Internal Medicine, School of Medicine, College of Medicine and Health Sciences, Dilla University, Dilla, Ethiopia; 2School of Public Health, College of Medicine and Health Sciences, Dilla University, Dilla, EthiopiaCorrespondence: Gizaw Sisay Tel +25191158 0679Email gizsisay@gmail.comIntroduction: Aminoglycosides are ototoxic drugs because they have the ability to destroy the inner ear structures irreversibly. They are used to treat Gram-negative bacterial infections that are aerobic and as a second-line treatment for tuberculosis.Case Presentation: A 40-year-old male from Dilla presented with right side chest pain and cough which is productive of whitish sputum of one-year duration, after investigation the diagnosis of multiple-drug resistant tuberculosis (MDR-TB) was made and the patient was started with a short-term MDR-TB treatment regimen (4– 6 KM-Mf-Pto-Cfz-Z-HH-E/5Mfx-Cfz-Z-E). Two and half months after the initiation of treatment, he developed decreased bilateral hearing ability and he had also vertigo, but this patient has no hearing impairment before the initiation of the anti-TB treatment. Then the diagnosis of sensor neural hearing loss secondary to drug toxicity (kanamycin) was made. Then the treatment was discontinued for four days as a result of ototoxicity and the patient was referred to Yirgalem Hospital for further workup and management.Conclusion: Injectable-containing MDR-TB regimens can cause permanent hearing loss. Hearing loss during treatment for MDR-TB with kanamycin can occur at any time. Systematic monitoring of AEs during and after the end of treatment needs to be strengthened in most TB programs. It is important to monitor for hearing loss and kidney function.Keywords: multiple-drug resistant tuberculosis, aminoglycosides, ototoxicity, Ethiopia, MDRTMantefardo BSisay GDove Medical Pressarticlemultiple-drug resistant tuberculosisaminoglycosidesototoxicityethiopiaMedicine (General)R5-920ENInternational Medical Case Reports Journal, Vol Volume 14, Pp 815-817 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	multiple-drug resistant tuberculosis aminoglycosides ototoxicity ethiopia Medicine (General) R5-920
spellingShingle	multiple-drug resistant tuberculosis aminoglycosides ototoxicity ethiopia Medicine (General) R5-920 Mantefardo B Sisay G Case Report: Kanamycin Ototoxicity and MDR-TB Treatment Regimen
description	Bahru Mantefardo,1 Gizaw Sisay2 1Department of Internal Medicine, School of Medicine, College of Medicine and Health Sciences, Dilla University, Dilla, Ethiopia; 2School of Public Health, College of Medicine and Health Sciences, Dilla University, Dilla, EthiopiaCorrespondence: Gizaw Sisay Tel +25191158 0679Email gizsisay@gmail.comIntroduction: Aminoglycosides are ototoxic drugs because they have the ability to destroy the inner ear structures irreversibly. They are used to treat Gram-negative bacterial infections that are aerobic and as a second-line treatment for tuberculosis.Case Presentation: A 40-year-old male from Dilla presented with right side chest pain and cough which is productive of whitish sputum of one-year duration, after investigation the diagnosis of multiple-drug resistant tuberculosis (MDR-TB) was made and the patient was started with a short-term MDR-TB treatment regimen (4– 6 KM-Mf-Pto-Cfz-Z-HH-E/5Mfx-Cfz-Z-E). Two and half months after the initiation of treatment, he developed decreased bilateral hearing ability and he had also vertigo, but this patient has no hearing impairment before the initiation of the anti-TB treatment. Then the diagnosis of sensor neural hearing loss secondary to drug toxicity (kanamycin) was made. Then the treatment was discontinued for four days as a result of ototoxicity and the patient was referred to Yirgalem Hospital for further workup and management.Conclusion: Injectable-containing MDR-TB regimens can cause permanent hearing loss. Hearing loss during treatment for MDR-TB with kanamycin can occur at any time. Systematic monitoring of AEs during and after the end of treatment needs to be strengthened in most TB programs. It is important to monitor for hearing loss and kidney function.Keywords: multiple-drug resistant tuberculosis, aminoglycosides, ototoxicity, Ethiopia, MDRT
format	article
author	Mantefardo B Sisay G
author_facet	Mantefardo B Sisay G
author_sort	Mantefardo B
title	Case Report: Kanamycin Ototoxicity and MDR-TB Treatment Regimen
title_short	Case Report: Kanamycin Ototoxicity and MDR-TB Treatment Regimen
title_full	Case Report: Kanamycin Ototoxicity and MDR-TB Treatment Regimen
title_fullStr	Case Report: Kanamycin Ototoxicity and MDR-TB Treatment Regimen
title_full_unstemmed	Case Report: Kanamycin Ototoxicity and MDR-TB Treatment Regimen
title_sort	case report: kanamycin ototoxicity and mdr-tb treatment regimen
publisher	Dove Medical Press
publishDate	2021
url	https://doaj.org/article/ace0f7f7de024dfda1bd22822cbdae6a
work_keys_str_mv	AT mantefardob casereportkanamycinototoxicityandmdrtbtreatmentregimen AT sisayg casereportkanamycinototoxicityandmdrtbtreatmentregimen
_version_	1718410545827151872

Case Report: Kanamycin Ototoxicity and MDR-TB Treatment Regimen

Ejemplares similares